
Recent EAU guidance and Saga reporting put low testosterone symptoms, repeat testing, fertility and TRT trade-offs into clinical context.

In its guideline dated 2026-11-03, the European Association of Urology (EAU) recommends assessing late-onset hypogonadism through compatible symptoms and repeated low morning testosterone results. Saga Magazine examined the implications for men considering testosterone replacement therapy (TRT) in an article published on 2026-11-05.
This article is for informational purposes and is not medical advice. Decisions about testing or treatment require assessment by a qualified healthcare professional.
According to the clinical commentary in Saga, sexual symptoms have a more consistent association with genuine testosterone deficiency than fatigue, low mood or concentration problems. The distinction matters because those less specific complaints can have other explanations.
This does not make fatigue or poor concentration unimportant. It means those symptoms do not point strongly enough toward testosterone deficiency to settle the question. The assessment needs to consider what someone is experiencing alongside blood results and other possible causes.
For a man researching his symptoms, two questions are worth separating: whether testosterone deserves investigation and whether testosterone treatment is appropriate. The first can lead to a clinical assessment. The second requires evidence of deficiency and a discussion of treatment.
A symptom list therefore has a limited role. It can help someone describe a concern, but it does not establish its cause. Understanding how symptoms fit alongside laboratory findings keeps that distinction clear without dismissing the symptoms themselves.
The EAU guideline recommends diagnosing late-onset hypogonadism using compatible symptoms together with low morning testosterone results on at least two occasions. It also specifies fasting conditions and a reliable assay, meaning a dependable laboratory measurement method.
The recommended assessment brings several elements together:
These are parts of an assessment rather than alternative routes to a diagnosis. Symptoms do not replace testing. A low laboratory result does not replace the assessment of symptoms and other explanations.
Saga notes that testosterone levels vary, which is one reason clinicians may repeat a measurement. The EAU guideline also advises confirming an abnormal result before testosterone therapy begins. Repetition is therefore part of establishing the finding rather than simply collecting another number.
The practical difference is between identifying a result that deserves attention and establishing a condition that may warrant treatment. A clinician considers both the clinical picture and whether the laboratory evidence meets the diagnostic approach.
For readers unfamiliar with this process, an explanation of why an initial testosterone assessment involves repeated measurements provides context. It is the relationship between the symptoms and the confirmed results that matters, not the isolated number alone.
Saga identifies obesity, type 2 diabetes and inactivity as possible contributors to lower testosterone. The EAU guideline likewise says low testosterone is common in men with obesity. It also describes a frequent association between hypogonadism and metabolic syndrome or related conditions.
These findings place hormone assessment within a wider health picture. A concern about testosterone is not necessarily separate from a discussion of metabolic health. Relevant conditions belong in the clinical assessment alongside symptoms and laboratory findings.
The wording matters here. A factor that may contribute to lower testosterone does not establish that every man with that factor has a hormone deficiency. Nor does the presence of a chronic condition establish that TRT is the appropriate response.
For clinical discussions, the useful question is how these factors affect the interpretation of symptoms and results. That leaves room to consider the broader health context rather than treating testosterone as an explanation for every change in energy or wellbeing.
Saga describes TRT as potentially useful for some men with genuine deficiency when diagnosis and monitoring are appropriate. That is a narrower proposition than raising testosterone whenever a man feels tired or receives a disappointing test result.
The distinction separates treatment of an established condition from increasing a laboratory number for its own sake. Whether treatment is worthwhile depends on the clinical assessment and the expected balance of benefit and harm for the individual.
Saga reports that unnecessary or excessive testosterone can cause fluid retention, breast tenderness and mood shifts. The article also notes that TRT can suppress the body’s own testosterone production and reduce sperm production.
The fertility issue deserves attention before a treatment decision. Saga advises men who hope to have children to discuss that with a doctor before starting TRT. Fertility plans are therefore part of the assessment rather than a separate concern to raise only after treatment begins.
Follow-up is another part of the treatment discussion. Saga describes testing before treatment and further testing over time. Monitoring should be considered alongside the decision to prescribe, not treated as an optional addition once treatment is underway.
The article also places these decisions within a wider debate about prescribing. It describes testosterone being considered for a broader population of men with chronic conditions and reports direct marketing by private clinics. Its account raises the question of how clinicians distinguish a genuine deficiency from common health problems that may have other explanations.
For someone weighing TRT, a useful discussion therefore includes the reason for treatment and the intended benefit. It also includes possible side effects, fertility implications and the follow-up that would be required. A promise of improved vitality does not answer those separate clinical questions.
The EAU recommendations discussed here concern late-onset hypogonadism. Saga is a magazine report combining clinical commentary with an account of diagnosis and treatment. This is guidance and reporting, not a newly reported clinical trial measuring the effects of TRT.
That distinction matters when interpreting claims about benefit. The material supports an assessment framework and a discussion of treatment trade-offs. It does not provide a measured treatment effect for men whose main concern is fatigue or poor concentration without confirmed deficiency.
Saga’s prevalence figures also need careful interpretation. It reports that around a quarter of men have a below-average testosterone reading. It separately reports that up to a fifth of men over 50 may report deficiency symptoms and that under 1% of men receive testosterone treatment under the NHS.
Those figures describe different things: laboratory readings, reported symptoms and treatment use. They are not interchangeable estimates of confirmed testosterone deficiency. They should not be treated as universal prevalence figures or combined into a calculation of how many men need TRT but are not receiving it.
The distinction between reported clinical opinion and measured outcomes also remains important. A clinician’s observation that some patients benefit is useful context. It is not proof that every man with similar complaints will experience the same result.
These boundaries keep the practical message focused: use the guideline to understand the assessment process and use the article’s commentary as context for a clinical conversation.
The information does not justify an immediate move toward prescribing testosterone more widely. Its clinical value is in reinforcing diagnosis-led care and making the treatment discussion more complete.
For a man with persistent sexual symptoms or other concerns, the supported next step is a conversation with a qualified clinician about whether testing is appropriate. That discussion can consider symptoms and alternative causes before moving to treatment questions.
Questions worth raising include:
These questions connect the guideline’s diagnostic approach with the decisions that matter in practice. They also separate the decision to investigate symptoms from the later decision about whether treatment offers a reasonable balance of benefits and risks.
The bottom line is not that testosterone concerns should be dismissed or that treatment is never worthwhile. It is that TRT belongs within care for appropriately assessed deficiency. This coverage reinforces that approach rather than establishing a new reason to treat common symptoms or pursue a higher testosterone number.
Interest in boosting testosterone can outpace an understanding of why symptoms occur, a gap Testostra addresses through evidence-led education. Its coverage connects questions about possible low testosterone symptoms with explanations of testing and related biomarkers, giving men clearer context for conversations with qualified clinicians rather than a suggested diagnosis or hormone protocol.
Testostra follows testosterone research, clinical guidance and emerging evidence without turning general information into personal treatment advice.




Send us a question, research idea or topic suggestion. Reader questions help shape future Testostra content.
Contact Testostra